




RealRate

PHARMACEUTICAL 2021

Apellis Pharmaceuticals Inc.
Rank 207 of 409

Apellis



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of Apellis Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Apellis Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 71% points. The greatest weakness of Apellis Pharmaceuticals Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is -137%, being 218% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	917,192
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	128,327
Liabilities, Non-Current	15,217
Other Assets	36,574
Other Compr. Net Income	37
Other Expenses	56,832
Other Liabilities	612,468
Other Net Income	-99,366
Property and Equipment	6,803
Research and Development	299,921
Revenues	250,646
Selling, General and Administrative Expense	139,401

Output Variable	Value in 1000 USD
Assets	960,569
Liabilities	756,012
Expenses	496,154
Stockholders Equity	204,557
Net Income	-344,874
Comprehensive Net Income	-344,856
Economic Capital Ratio	-137%